Detection of multiple myeloma by PET/CT in a patient with colon cancer.

Clin Nucl Med

Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, People's Republic of China.

Published: May 2008

A 76-year-old man with previous sigmoid colon resection for adenocarcinoma had low back pain for 2 months. Whole-body bone scintigraphy showed multiple focal Tc-99m methylene diphosphonate (MDP)-avid lesions in both rib cages and 3 lumbar vertebrae, indicating metastases. F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging was performed for further evaluation of this possible metastatic disease and demonstrated the lumbar and costal metastases and several hypermetabolic areas in the pelvic bones, multiple thoracic vertebrae, both shoulders, and the right femur. Histopathologic examination of the right-sided iliac crest, however, revealed multiple myeloma.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0b013e31816a8883DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
8
detection multiple
4
myeloma pet/ct
4
pet/ct patient
4
patient colon
4
colon cancer
4
cancer 76-year-old
4
76-year-old man
4
man previous
4
previous sigmoid
4

Similar Publications

Introduction: Mitochondria and angiogenesis play key roles in multiple myeloma (MM) development, but their interrelated genes affecting MM prognosis are under-studied.

Methods: We analyzed TCGA_MMRF and GSE4581 datasets to identify four genes - CCNB1, CDC25C, HSP90AA1, and PARP1 - that significantly correlate with MM prognosis, with high expression indicating poor outcomes.

Results: A prognostic signature based on these genes stratified patients into high- and low-risk groups, with the latter showing better survival.

View Article and Find Full Text PDF

Background: Secondary acute lymphoblastic leukemia (sALL) is rare in patients diagnosed with antecedent multiple myeloma (MM). This study aimed to elucidate the clinical features and outcomes of patients with sALL after MM.

Methods: We conducted this population-based study using the Surveillance, Epidemiology, and End Results (SEER) database and retrospectively reviewed patients with sALL following MM treatment at our institution.

View Article and Find Full Text PDF

Multiple myeloma (MM) represents a difficult-to-treat plasma cell malignancy and the second most common hematologic malignancy in adults, significantly impacting kidney function. The spectrum of kidney involvement in MM is broad, encompassing electrolyte imbalances, tubular injury, and even rare glomerular diseases. The evolution of MM treatment modalities has led to notable improvements in the long-term survival of patients experiencing kidney-related complications.

View Article and Find Full Text PDF

Background: Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the efficacy and safety of anti-CD38 mAb-based therapy versus standard therapy in newly diagnosed multiple myeloma (NDMM) patients.

Methods: We performed a comprehensive literature search on PubMed, the Cochrane Database, and ClinicalTrials.

View Article and Find Full Text PDF

Treatment options for older adults with relapsed multiple myeloma are constrained by the toxicities of existing treatments, the ageing-associated vulnerabilities that may increase the risk of poor treatment tolerance and patient preferences for treatments that do not impair their function or cognition. The study by Toussea et al. epitomizes approaches to designing trials specifically for more vulnerable older adults and moves the field forward with a regimen of great interest for older adults experiencing their first relapse.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!